Myeloma
Indy Hematology Review
Emerging and Current Treatment of MM: What Should We Know and What Should We Do
FEATURING
Kenneth Anderson
- 367 views
- April 18, 2023
- 1
Yale Cancer Center
Early Detection and Interception in Myeloma: The PROMISE Study
FEATURING
Irene Ghobrial
- 101 views
- March 22, 2023
- 1
Dana-Farber Cancer Institute
Updates on Managing Bone Disease in Multiple Myeloma
FEATURING
Monique Hartley-Brown
- 38 views
- March 9, 2023
Dana-Farber Cancer Institute
Bispecific Antibodies in Multiple Myeloma
FEATURING
Omar Nadeem
- 168 views
- March 9, 2023
Dana-Farber Cancer Institute
Symptom Management in Multiple Myeloma
FEATURING
Shonali Midha
- 129 views
- March 9, 2023
Dana-Farber Cancer Institute
Update on CAR T-Cells in Multiple Myeloma
FEATURING
Adam Sperling
- 98 views
- March 9, 2023
Dana-Farber Cancer Institute
Updates on AL Amyloidosis Treatment: What is New in 2023
FEATURING
Giada Bianchi
- 248 views
- March 9, 2023
- 1
Dana-Farber Cancer Institute
The Ongoing Evolution of Systemic Therapy for ND Multiple Myeloma
FEATURING
Clifton Mo
- 17 views
- March 9, 2023
Dana-Farber Cancer Institute
Future Directions for Novel & Next Gen Therapy in the Management of MM: A Clinical Perspective
FEATURING
Paul Richardson
- 277 views
- March 9, 2023
- 4
Dana-Farber Cancer Institute
The PROMISE of Early Detection and Interception in Myeloma
FEATURING
Irene Ghobrial
- 183 views
- March 9, 2023
Dana-Farber Cancer Institute
Recent Updates in Multiple Myeloma
FEATURING
Kenneth Anderson
- 592 views
- March 9, 2023
- 7
Dana-Farber Cancer Institute
Myeloma 101: Diagnosis, Prognosis & Risk
FEATURING
Nikhil Munshi
- 290 views
- March 9, 2023
ASH 2022 Conference Coverage
ASH 2022 Subsequent Antimyeloma Therapies From ICARIA-MM Study: Pom/Low-Dose Dex +/- Isa in Patients With R/R Myeloma
FEATURING
Paul Richardson
- 95 views
- January 18, 2023
- 2
Dana-Farber Cancer Institute
Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenance to Progression in NDMM by Cytogenetic Risk
FEATURING
Paul Richardson
- 375 views
- September 6, 2022
- 3
Dana-Farber Cancer Institute
2022 Treatment Landscape and Future Directions of R/R Multiple Myeloma
FEATURING
Nikhil Munshi
- 451 views
- February 2, 2022
- 1
Dana-Farber Cancer Institute
EHA 2020 ICARIA-MM Data on Isatuximab in R/R Multiple Myeloma: Does mAb Combined With Pd Prolong PFS?
FEATURING
Paul Richardson
- 239 views
- January 19, 2021
Dana-Farber Cancer Institute
Waldenström Macroglobulinemia - Standard Treatment Options and Review of Recent Clinical Trials
FEATURING
Jorge Castillo
- 239 views
- October 11, 2018
- 1
Dana-Farber Cancer Institute
Relapse Refractory Myeloma and Novel Treatments
FEATURING
Noopur S. Raje
- 233 views
- June 22, 2018
- 1
Dana-Farber Cancer Institute
Is it Time to Treat Patients with Smoldering Myeloma in 2018?
FEATURING
Irene Ghobrial
- 197 views
- June 22, 2018
- 1
Dana-Farber Cancer Institute
2016 Multiple Myeloma Patient Education Symposium: Novel Treatments With a Focus on Bone Disease
FEATURING
Noopur S. Raje
- 123 views
- December 19, 2017